American Portfolios Advisors’s Atara Biotherapeutics ATRA Stock Holding History

American Portfolios Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$17K	Sell	180 -174	-49%	-$19.5K	﹤0.01%	2270
2022 Q2	$68.9K	Hold	354	–	–	﹤0.01%	1596
2022 Q1	$82.2K	Buy	354 +10	+3%	+$3.18K	﹤0.01%	1622
2021 Q4	$136K	Sell	344 -20	-5%	-$8.42K	﹤0.01%	1363
2021 Q3	$163K	Buy	364 +239	+191%	+$85.6K	0.01%	1215
2021 Q2	$48.6K	Buy	125 +59	+89%	+$21K	﹤0.01%	1740
2021 Q1	$23.7K	Buy	66 +21	+47%	+$9.28K	﹤0.01%	1980
2020 Q4	$22.1K	Buy	+45	New	+$20.8K	﹤0.01%	1769

Other funds holding ATRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Portfolios Advisors's ATRA Position: Q3 2022 in Review

American Portfolios Advisors reduced its Atara Biotherapeutics (ATRA) stake by 49% in Q3 2022, selling an estimated $19.5K and leaving 180 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

American Portfolios Advisors first reported a position in ATRA in Q4 2020 and has held it in 8 quarters since. The position peaked at $163K in Q3 2021. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

American Portfolios Advisors held 180 shares of Atara Biotherapeutics worth $17K as of Q3 2022.
American Portfolios Advisors sold 174 Atara Biotherapeutics shares in Q3 2022, an estimated $19.5K.
Atara Biotherapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2270 holding.
American Portfolios Advisors first reported a position in Atara Biotherapeutics in Q4 2020 and has held it in 8 quarters since.
American Portfolios Advisors's Atara Biotherapeutics position peaked at $163K in Q3 2021.
154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.